Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Non-Current Liabilities (2018 - 2023)

China Pharma Holdings (CPHI) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $2.2 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Other Non-Current Liabilities changed N/A year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Mar 2023, changed N/A, and an annual FY2022 reading of $2.4 million, up 26.85% over the prior year.
  • Other Non-Current Liabilities was $2.2 million for Q1 2023 at China Pharma Holdings, down from $2.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.1 million in Q2 2021 and bottomed at $1.7 million in Q3 2021.
  • Average Other Non-Current Liabilities over 5 years is $2.3 million, with a median of $2.4 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities crashed 31.44% in 2021, then increased 26.85% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $2.4 million in 2019, then grew by 14.44% to $2.7 million in 2020, then plummeted by 31.44% to $1.9 million in 2021, then grew by 26.85% to $2.4 million in 2022, then dropped by 9.15% to $2.2 million in 2023.
  • Business Quant data shows Other Non-Current Liabilities for CPHI at $2.2 million in Q1 2023, $2.4 million in Q4 2022, and $1.9 million in Q4 2021.